1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > General Anxiety Disorder-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ General Anxiety Disorder-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under General Anxiety Disorder. This report provides information on the therapeutic development based on the General Anxiety Disorder dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of General Anxiety Disorder
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the General Anxiety Disorder pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for General Anxiety Disorder and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for General Anxiety Disorder
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding General Anxiety Disorder pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

General Anxiety Disorder-Pipeline Insights, 2014
Table of Contents
- General Anxiety Disorder Overview
- General Anxiety Disorder Pipeline Therapeutics
- General Anxiety Disorder Therapeutics under Development by Companies
- General Anxiety Disorder Late Stage Products (Filed and Phase III)
- Comparative Analysis
- General Anxiety Disorder Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- General Anxiety Disorder Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- General Anxiety Disorder Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- General Anxiety Disorder - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- General Anxiety Disorder - Discontinued Products
- General Anxiety Disorder - Dormant Products
- Companies Involved in Therapeutics Development for General Anxiety Disorder
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for General Anxiety Disorder, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- General Anxiety Disorder Assessment by Monotherapy Products
- General Anxiety Disorder Assessment by Combination Products
- General Anxiety Disorder Assessment by Route of Administration
- General Anxiety Disorder Assessment by Stage and Route of Administration
- General Anxiety Disorder Assessment by Molecule Type
- General Anxiety Disorder Assessment by Stage and Molecule Type
- General Anxiety Disorder Therapeutics - Discontinued Products
- General Anxiety Disorder Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for General Anxiety Disorder, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- General Anxiety Disorder Assessment by Monotherapy Products
- General Anxiety Disorder Assessment by Combination Products
- General Anxiety Disorder Assessment by Route of Administration
- General Anxiety Disorder Assessment by Stage and Route of Administration
- General Anxiety Disorder Assessment by Molecule Type
- General Anxiety Disorder Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 - 2025

Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • December 2016
  • by Grand View Research

The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth ...

Anxiety Disorders-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

Anxiety Disorders-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

  • $ 2000
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Report, “Anxiety Disorders-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III ...

 General Anxiety Disorder-Pipeline Insights, 2017

General Anxiety Disorder-Pipeline Insights, 2017

  • $ 1250
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s, “ General Anxiety Disorder-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the General Anxiety Disorder. ...


Download Unlimited Documents from Trusted Public Sources

Mental Health Statistics in the UK

  • February 2017
    82 pages
  • Mental Health  

    Hospital  

  • United Kingdom  

View report >

Diabetes Statistics

  • February 2017
    4 pages
  • Diabetes  

    Depression  

    Mental Health  

View report >

Diabetes Statistics

  • February 2017
    4 pages
  • Diabetes  

    Depression  

    Mental Health  

View report >

Related Market Segments :

Anxiety Disorder

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.